Interpretation
The outcomes of this trial suggest that successful treatment of ID can
occur with a single 1000mg dose, with no adverse outcomes for antenatal
progression, neonatal or child outcomes. This represents an effective
treatment modality to shield from the detrimental short- and potential
long-term impacts of ID and IDA. Further, adequate iron stores have the
potential to positively impact maternal mental health during pregnancy
and post-partum; maternal mental health outcomes collected during this
trial will be the subject of a subsequent article. Further studies will
help to optimise IVI dose, which may be particularly relevant to those
countries where 1000mg is not currently routinely used.